These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21804109)

  • 1. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
    Verschuren JJ; Trompet S; Wessels JA; Guchelaar HJ; de Maat MP; Simoons ML; Jukema JW
    Eur Heart J; 2012 Jan; 33(2):165-75. PubMed ID: 21804109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics and the potential for personalized therapeutics in cardiovascular disease.
    Kayser SR
    Prog Cardiovasc Nurs; 2007; 22(2):104-7. PubMed ID: 17541322
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenetics of the antiplatelet effect of aspirin.
    Würtz M; Kristensen SD; Hvas AM; Grove EL
    Curr Pharm Des; 2012; 18(33):5294-308. PubMed ID: 22724416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management.
    Humma LM; Terra SG
    Am J Health Syst Pharm; 2002 Jul; 59(13):1241-52. PubMed ID: 12116890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetics of aspirin resistance.
    Goodman T; Sharma P; Ferro A
    Int J Clin Pract; 2007 May; 61(5):826-34. PubMed ID: 17391325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics in cardiovascular diseases.
    Mukherjee D; Topol EJ
    Curr Probl Cardiol; 2003 May; 28(5):317-47. PubMed ID: 14614445
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical application of cardiovascular pharmacogenetics.
    Voora D; Ginsburg GS
    J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular therapeutics.
    Shakur R; Cockrum E; Scott D
    Br J Hosp Med (Lond); 2008 Sep; 69(9):M136-40. PubMed ID: 18819300
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular pharmacogenetics.
    Myburgh R; Hochfeld WE; Dodgen TM; Ker J; Pepper MS
    Pharmacol Ther; 2012 Mar; 133(3):280-90. PubMed ID: 22123178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
    Cavallari LH; Mason DL
    Adv Chronic Kidney Dis; 2016 Mar; 23(2):82-90. PubMed ID: 26979147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of Lipid-lowering Therapies.
    Ordovas JM; Shen H
    Curr Atheroscler Rep; 2002 May; 4(3):183-92. PubMed ID: 11931715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of genetic data to guide therapy in arterial disease.
    Ross S; Nejat S; Paré G
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S281-9. PubMed ID: 26149037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.
    Predazzi IM; Mango R; Norata GD; Di Daniele N; Sergi D; Romeo F; Novelli G
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):79-85. PubMed ID: 23539170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450-mediated cardiovascular drug interactions.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1065-82. PubMed ID: 21810031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based medical therapy of patients with acute coronary syndromes.
    Ramanath VS; Eagle KA
    Am J Cardiovasc Drugs; 2007; 7(2):95-116. PubMed ID: 17503881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).
    Lamoureux F; Duflot T;
    Therapie; 2017 Apr; 72(2):257-267. PubMed ID: 28237404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.
    Feher G; Koltai K; Papp E; Alkonyi B; Solyom A; Kenyeres P; Kesmarky G; Czopf L; Toth K
    Drugs Aging; 2006; 23(7):559-67. PubMed ID: 16930084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
    Huber K; Bates ER; Valgimigli M; Wallentin L; Kristensen SD; Anderson JL; Lopez Sendon JL; Tubaro M; Granger CB; Bode C; Ohman EM; Steg PG
    Am Heart J; 2014 Nov; 168(5):611-21. PubMed ID: 25440788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized medicine and antiplatelet therapy: ready for prime time?
    Verstuyft C; Simon T; Kim RB
    Eur Heart J; 2009 Aug; 30(16):1943-63. PubMed ID: 19638479
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenetics of chronic cardiovascular drugs: applications and implications.
    Zineh I; Johnson JA
    Expert Opin Pharmacother; 2006 Aug; 7(11):1417-27. PubMed ID: 16859425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.